United Capital Financial Advisors LLC Invests $595,000 in Revolution Medicines, Inc. $RVMD

United Capital Financial Advisors LLC bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,175 shares of the company’s stock, valued at approximately $595,000.

Several other large investors have also modified their holdings of RVMD. Equitable Holdings Inc. bought a new stake in Revolution Medicines in the second quarter valued at about $963,000. Public Employees Retirement System of Ohio bought a new position in Revolution Medicines during the 2nd quarter worth approximately $14,496,000. Capstone Investment Advisors LLC bought a new position in Revolution Medicines during the 2nd quarter worth approximately $1,348,000. Seven Fleet Capital Management LP grew its position in shares of Revolution Medicines by 199.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 242,029 shares of the company’s stock worth $45,327,000 after acquiring an additional 161,237 shares in the last quarter. Finally, Corient Private Wealth LP acquired a new position in shares of Revolution Medicines in the 2nd quarter worth approximately $1,523,000. Institutional investors own 94.34% of the company’s stock.

Insider Activity at Revolution Medicines

In other news, Director Sushil Patel sold 5,580 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the transaction, the director owned 21,656 shares of the company’s stock, valued at approximately $4,071,111.44. The trade was a 20.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mark A. Goldsmith sold 80,000 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the transaction, the insider owned 267,330 shares of the company’s stock, valued at $55,925,436. This represents a 23.03% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 212,497 shares of company stock valued at $38,206,486. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Trading Down 1.1%

Shares of NASDAQ RVMD opened at $205.57 on Tuesday. The company has a market cap of $44.06 billion, a price-to-earnings ratio of -23.31 and a beta of 1.39. Revolution Medicines, Inc. has a 12-month low of $37.56 and a 12-month high of $224.31. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The stock’s 50 day simple moving average is $194.12 and its 200 day simple moving average is $149.73.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the business posted ($1.31) earnings per share. Equities research analysts expect that Revolution Medicines, Inc. will post -8.85 EPS for the current year.

Analysts Set New Price Targets

RVMD has been the topic of several research reports. UBS Group upped their price target on Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research report on Friday. Evercore reaffirmed an “outperform” rating and issued a $320.00 price objective on shares of Revolution Medicines in a report on Thursday. Sanford C. Bernstein boosted their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research note on Friday, August 21st. HC Wainwright increased their target price on shares of Revolution Medicines from $195.00 to $280.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Truist Financial raised their price target on shares of Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Revolution Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $200.74.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.